Racial Comparison of Receptor-Defined Breast Cancer in Southern African Women: Subtype Prevalence and Age–Incidence Analysis of Nationwide Cancer Registry Data

Background: Receptor-defined breast cancer proportions vary across Africa. They have important implications for survival prospects and research priorities. Methods: We studied estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor statuses in two multiracial Southern African countries with routine diagnostic immunohistochemistry. A total of 12,361 women with histologically confirmed breast cancer diagnosed at age ≥20 years during (i) 2009–2011 from South Africa's national cancer registry (public sector) and (ii) 2011–2013 from Namibia's only cancer hospital were included. Crude, age, and age + laboratory–adjusted ORs of receptor status were analyzed using logistic regression, and age–incidence curves were analyzed using Poisson regression. Results: A total of 10,047 (81%) women had known ER status. Ranking of subtypes was consistent across races: ER+/PR+HER2− was most common (race-specific percentage range, 54.6%–64.8%), followed by triple-negative (17.4%–21.9%), ER+/PR+HER2+ (9.6%–13.9%), and ER−PR−HER2+ (7.8%–10.9%). Percentages in black versus white women were 33.8% [95% confidence (CI), 32.5–35.0] versus 26.0% (24.0–27.9) ER−; 20.9% (19.7–22.1) versus 17.5% (15.4–19.6) triple-negative; and 10.7% (9.8–11.6) versus 7.8% (6.3–9.3) ER−PR−HER2+. Indian/Asian and mixed-ancestry women had intermediate values. Age–incidence curves had similar shapes across races: rates increased by 12.7% per year (12.2–13.1) across ER subtypes under the age of 50 years, and thereafter slowed for ER+ (1.95%) and plateaued for ER− disease (−0.1%). Conclusions: ER+ breast cancer dominates in all Southern African races, but black women have a modest excess of aggressive subtypes. Impact: On the basis of the predominant receptor-defined breast tumors in Southern Africa, improving survival for the growing breast cancer burden should be achievable through earlier diagnosis and appropriate treatment. Cancer Epidemiol Biomarkers Prev; 23(11); 2311–21. ©2014 AACR.

[1]  A. Neugut,et al.  Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series , 2013, Breast Cancer Research.

[2]  I. Smith,et al.  Endocrine therapy for advanced/metastatic breast cancer. , 2013, Hematology/oncology clinics of North America.

[3]  J. Lawn,et al.  Health in South Africa: changes and challenges since 2009 , 2012, The Lancet.

[4]  T. Moultrie,et al.  Birth intervals, postponement, and fertility decline in Africa: A new type of transition? , 2012, Population studies.

[5]  O. Olopade,et al.  High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients , 2012, International journal of cancer.

[6]  A. Jemal,et al.  Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women? , 2012, Breast Cancer Research and Treatment.

[7]  I. Ellis,et al.  Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women , 2012, Breast Cancer Research and Treatment.

[8]  A. Kurian,et al.  Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. , 2012, Journal of the National Cancer Institute.

[9]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[10]  V. Beral,et al.  Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study , 2012, PLoS medicine.

[11]  K. Nkrumah,et al.  Breast cancer in Kumasi, Ghana. , 2012, Ghana medical journal.

[12]  M. Adeoti,et al.  Non-adherence to the Use of Tamoxifen in the First year by the Breast Cancer Patients in an African Population , 2011 .

[13]  Paul Augustine,et al.  Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. , 2011, Journal of the National Cancer Institute.

[14]  Philip S Rosenberg,et al.  Incidence of breast cancer in the United States: current and future trends. , 2011, Journal of the National Cancer Institute.

[15]  D. Mozaffarian,et al.  Non-communicable diseases in sub-Saharan Africa: what we know now. , 2011, International journal of epidemiology.

[16]  C. Adebamowo,et al.  Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. , 2011, The Lancet. Oncology.

[17]  Marilys Corbex,et al.  Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. , 2011, Breast.

[18]  Victoria L. Cafourek,et al.  Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.

[19]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[20]  L. Newman,et al.  African ancestry and higher prevalence of triple‐negative breast cancer , 2010, Cancer.

[21]  N. Maniadakis,et al.  Pharmacoeconomic considerations in the treatment of breast cancer , 2010, ClinicoEconomics and outcomes research : CEOR.

[22]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[23]  C. Perou,et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Sneeringer.  Fertility transition in sub-Saharan Africa: a comparative analysis of cohort trends in 30 countries , 2009 .

[25]  S. Norris,et al.  University of Birmingham Age at menarche and the evidence for a positive secular trend in urban South Africa , 2015 .

[26]  Clive R Taylor,et al.  Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[27]  S. Tishkoff,et al.  African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. , 2008, Annual review of genomics and human genetics.

[28]  J. Yarney,et al.  Hormone Receptor and HER‐2 Expression in Breast Cancers Among Sub‐Saharan African Women , 2008, The breast journal.

[29]  S. Anyanwu.  Temporal trends in breast cancer presentation in the third world , 2008, Journal of experimental & clinical cancer research : CR.

[30]  A. Adisa,et al.  Paradox of wellness and nonadherence among Nigerian women on breast cancer chemotherapy. , 2008, Journal of cancer research and therapeutics.

[31]  C. Adebamowo,et al.  Immunohistochemical and molecular subtypes of breast cancer in Nigeria , 2008, Breast Cancer Research and Treatment.

[32]  M. Galukande,et al.  Cancer of the breast: 5-year survival in a tertiary hospital in Uganda , 2008, British Journal of Cancer.

[33]  Odd O Aalen,et al.  Breast cancer tumor growth estimated through mammography screening data , 2008, Breast Cancer Research.

[34]  P. Blasio,et al.  Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa , 2008, Histopathology.

[35]  K. Sikora,et al.  Overcoming challenges of cancer treatment programmes in developing countries: a sustainable breast cancer initiative in Ethiopia. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[36]  S. Frank.  Dynamics of Cancer: Incidence, Inheritance, and Evolution , 2007 .

[37]  M. van der Merwe,et al.  Obesity in South Africa , 2006, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[38]  W. Anderson,et al.  Breast cancer heterogeneity: a mixture of at least two main types? , 2006, Journal of the National Cancer Institute.

[39]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[40]  L. Newman,et al.  Breast cancer in sub‐Saharan Africa: How does it relate to breast cancer in African‐American women? , 2005, Cancer.

[41]  T. Moultrie,et al.  The South African fertility decline: Evidence from two censuses and a Demographic and Health Survey , 2003, Population studies.

[42]  A. Ellis.  Breast , 2002, BMJ : British Medical Journal.

[43]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[44]  W. Gould,et al.  A fertility transition in Sub-Saharan Africa? , 1996, International journal of population geography : IJPG.

[45]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[46]  S. Merajver,et al.  Clinical and epidemiologic profile of breast cancer in Tanzania. , 2010, Breast disease.

[47]  Fracs P. A. Bird MBBS,et al.  Poor Hormone Receptor Expression in East African Breast Cancer: Evidence of a Biologically Different Disease? , 2008, Annals of Surgical Oncology.

[48]  S. Frank.  Age of Cancer Incidence , 2007 .

[49]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.